Drug Trial Radar · NCT07348484
Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Apr 1, 2026
Primary completion
Apr 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Instituto de Investigación Biomédica de SalamancaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 16, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with chronic kidney disease (CKD) stages 2-4 (KDIGO classification). The study will also validate a urinary biomarker panel for early diagnosis and monitoring of CKD progression. No investigational product is assigned, and medical practice or prescription patterns are not altered.
Conditions
- Chronic Kidney Disease
Interventions
EmpagliflozinDrug
Oral empagliflozin (10-25 mg daily) for 12 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in urinary biomarker panel expression (proteomic fingerprint)Time frame: Baseline, 6 months, 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Universitario de Salamanca
Salamanca, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.